METTL3 induced the upregulation of SNHG17 via stabilizing its mRNA, and SNHG17 recruited EZH2 to the promoter region of large tumor suppressor kinase 2 (LATS2) to suppress it expression, which was a well-known tumor suppressor involved in the Hippo cascade, then epigenetically repressed LATS2 promote resistance to gefitinib in LUAD [108]. This evidence concerns the gene LATS2 and neoplasm.